Oncolytic Virus Cancer Therapy Market Insights, Epidemiology and Forecasts, 2019-2021 & 2022-2032 – Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Oncolytic Virus Cancer Therapy – Market Insight, Epidemiology and Market Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering.

The Oncolytic Virus Therapies (OVTs) market report provides emerging drugs, Oncolytic Virus Therapies (OVTs) market share of the individual cancer types, current and forecasted Oncolytic Virus Therapies (OVTs) market size from 2019 to 2032 segmented by seven major markets. The Report also covers current OVTs unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Oncolytic Virus Therapies (OVTs) Understanding and Treatment Algorithm

OVs have proven to be a powerful anticancer molecule, being able to be used for cancer diagnosis as well as treatment. Their multifunctional characteristics indicate good application prospects as cancer therapeutics, especially in combination with other therapies, such as radiotherapy, chemotherapy, and immunotherapy.

Currently, only two oncolytic virus therapies are approved, namely, IMLYGIC (Talimogene laherparepvec/T-VEC; Amgen) approved in the US and Europe in 2015, and DELYTACT (teserpaturev/G47∆; Daiichi Sankyo) approved in Japan in 2021.

Oncolytic Virus Therapies (OVTs) Epidemiology

The epidemiology section provides the insights about historical and current indication wise eligible patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Oncolytic Virus Therapies (OVTs) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

In 2021, the total indication wise target patient pool cases across 7MM were about 632 K which are expected to grow during the study period, i.e., 2019-2032.

Drug Chapters

The drug chapter segment of the Oncolytic Virus Therapies (OVTs) report encloses the detailed analysis of OVTs marketed drugs and late stage (Phase III and Phase II) pipeline drugs. It also helps to understand the OVTs clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Emerging Drugs

The report provides the details of the emerging OVTs under the late and mid-stage of development for selected indications treatment.

Oncolytic Virus Therapies (OVTs) Market Outlook

The Oncolytic Virus Therapies (OVTs) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted OVTs market trends by analyzing the impact of current therapies on the market, unmet needs, and demand of better technology.

This segment gives a thorough detail of OVTs market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Key Findings

The OVTs market size in the 7MM is expected to change during the study period 2019-2032. The OVTs therapeutic market in the seven major markets is expected to increase during the study period (2019-2032). In 2021, the total market size of OVTs was approximately USD 122 million which is expected to rise during the study period (2019-2032).

The United States Market Outlook

The total market size of OVTs in the United States accounted for USD 84 million in 2021 which is expected to rise during the study period (2019-2032).

EU-5 Countries: Market Outlook

In EU5, the total market size of OVTs was about USD 38 million in 2021, which is expected to rise during the study period (2019-2032).

Japan Market Outlook

In Japan, the total market size of OVTs was USD 0.01 million in 2021, which is expected to rise during the study period (2019-2032).

Oncolytic Virus Therapies (OVTs) Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the OVTs market or expected to get launched in the market during the study period 2019-2032. The analysis covers Oncolytic Virus Therapies (OVTs) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Oncolytic Virus Therapies (OVTs) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses key players involved in developing OVTs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing patent details, and other information for emerging OVTs.

Reimbursement Scenario in Oncolytic Virus Therapies (OVTs)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL-Views

To keep up with current market trends, we take KOLs and SMEs ‘ opinions working in the OVTs domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or OVTs market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitively and Market Intelligence analysis of the OVTs Market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Report Highlights

• In the coming years, OVTs market is set to change due to improved patient outcomes, treatment of cold tumors, rich emerging pipeline and convenient production and administration; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence OVTs R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for OVTs. Launch of emerging therapies, will significantly impact the OVTs market.
• This in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Marketed therapies

• IMLYGIC (talimogene laherparepvec): Amgen
• DELYTACT (G47∆): Daiichio Sankyo

Emerging Therapies

• ONCOS-102: Targovax
• RP1 (Vusolimogene Oderparepvec): Replimune
• GL-ONC1: Genelux Corporation
• CAN-2409: Candel Therapeutics
• DNX-2401 (Tasadenoturev): DNAtrix
• PEXA-VEC (Pexastimogene Devacirepvec; JX-594): SillaJen
• G207: Treovir
• LOAd703: Lokon Pharma AB
• Lerapolturev (Formerly Known as PVSRIPO): Istari Oncology
• CG0070: CG Oncology

Market Access and Reimbursement

• NICE UK
• IQWiG and GBA Assessment
• Japan
• Patient assistance programs

Companies Mentioned

• Targovax
• Replimune
• Genelux Corporation
• Candel Therapeutics
• DNAtrix
• SillaJen
• Treovir
• Lokon Pharma AB
• Istari Oncology
• CG Oncology
• Amgen
• Daiichio Sankyo

For more information about this report visit https://www.researchandmarkets.com/r/bx0wzf

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900